Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Early prediction of pathologic response to neoadjuvant treatment of breast cancer: use of a cell-loss metric based on serum thymidine kinase 1 and tumour volume

Fig. 1

Receiver operating characteristic for distinguishing pCR from remaining tumour in 104 women, based on the cell-loss metric 48 h after the 2nd treatment cycle. At a cut-off value of 0.026 for the cell-loss metric, 1-specificity and sensitivity were 0.31 and 0.71, respectively. ROC Area = 0.714, p = 0.02

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us